1. Sotirios Giannopoulosa, Athanassios P. Kyritsis Diagnosis and Management of Multifocal Gliomas. Oncology. 2010;79:306–12.
2. Hassaneen W, Levine NB, Suki D, Salaskar AL, de Moura LA, McCutcheon IE, et al. Multiple craniotomies in the management of multifocal and multicentric glioblastoma. Clinical article J Neurosurg. 2011;114:576–84.
3. Showalter TN, Andrel J, Andrews DW, Curran Jr WJ, Daskalakis C, Werner-Wasik M. Multifocal glioblastoma multiforme: prognostic factors and patterns of progression. Int J Radiat Oncol Biol Phys. 2007;69:820–4.
4. Lou E, Peters KB, Sumrall AL, Desjardins A, Reardon DA, Lipp ES, Herndon JE, Coan A, Bailey L, Turner S, Friedman HS, Vredenburgh JJ. Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma. Cancer Medicine. 2013;2:185–95.
5. Nomiya T, Nemoto K, Kumabe T, Takai Y, Yamada S: Prog- nostic significance of surgery and radiation therapy in cases of anaplastic astrocytoma: retrospective analysis of 170 cases. J Neurosurg. 2007;106:575–81.
6. Ampil F, Burton GV, Gonzalez-Toledo E, Nanda A. Do we need whole brain irradiation in multifocal or multicentric high-grade cerebral gliomas? Review of cases and the literature. J Neurooncol. 2007; 85:353–5.
7. Djalilian HR, Shah MV, Hall WA. Radiographic incidence of multicentric malignant gliomas. Surg Neurol. 1999;51:554–8.
8. Thomas RP, Xu LW, Lober RM, Li G, Nagpal S. The incidence and significance of multiple lesions in glioblastoma. J Neurooncol. 2013;112:91–7.
9. Franco CM, Malheiros SM, Nogueira RG, Batista MA, Santos AJ, Abdala N, et al. Multiple gliomas. Illustrative cases of 4 different presentations. Arq Neuropsiquiatr. 2000;58:150–6.
10. Kyritsis AP, Yung WKA, Leeds NE, Bruner J, Gleason MJ, Levin VA. Multifocal cerebral gliomas associated with secondary malignancies. Lancet. 1992;339:1229–30.
11. Kudo H, Tanaka M, Urui S, Suzuki H, Tamaki N, Matsumoto S. Multicentric glioblastoma multiforme occurring in the supra- and the infratentorial regions: case report. Neurol Med Chir. 1990;30:334–8.
12. Synowitz M, von Eckardstein K, Brauer C, Hoch HH, Kiwit JC. Case history: multicentric glioma with involvement of the optic chiasm. Clin Neurol Neurosurg. 2002;105:66–8.
13. Turola MC, Schivalocchi R, Ramponi V, De Vito A, Nanni MG, Frivoli GF: A rare case of multicentric synchronous bi-frontal glioma in a young female. Diagnostic and therapeu- tic problems: a case report. Cases J. 2009;2:81.
14. Salvati M, Caroli E, Orlando ER, Frati A, Ar- tizzu S, Ferrante L: Multicentric glioma: our experience in 25 patients and critical review of the literature. Neurosurg Rev. 2003;26:275–9.
15. Kyritsis AP, Bondy ML, Xiao M, Berman EL, Cunningham JE, Lee PS, Levin VA, Saya H. Germline p53 gene mutations in subsets of glioma patients. J Natl Cancer Inst. 1994;86:344–9.
16. Baldock AL, Yagle K, Born DE, Ahn S, Trister AD, Neal M, Johnston SK, Bridge CA, Basanta D, Scott J, Malone H, Sonabend AM, Canoll P, Mrugala MM, Rockhill JK, Rockne RC, Swanson KR. Invasion and proliferation kinetics in enhancing gliomas predict IDH1 mutation status. Neuro-oncology. 2014;16:779–86.
17. Carrillo JA, Lai A, Nghiemphu PL, Kim HJ, Phillips HS, Kharbanda S, Moftakhar P, Lalaezari S, Yong W, Ellingson BM, Cloughesy TF, Pope WB. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR Am J Neuroradiol. 2012;33:1349–55.
18. Eoli M, Menghi F, Bruzzone MG, De Simone T, Valletta L, Pollo B, et al. Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clin Cancer Res. 2007;13:2606–13.
19. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008;26:4189–99.
20. Di Carlo DT, Cagnazzo F, Benedetto N, Morganti R, Perrini P. Multiple high-grade gliomas: epidemiology, management, and outcome. A systematic review and meta-analysis. Neurosurg Rev. 2017.
21. Kyritsis AP, Rao JS, Puduvalli VK. Prognostic factors in multifocal gliomas: in regard to Showalter et al. (Int J Radiat Oncol Biol Phys 2007;69:820–824). Int J Radiat Oncol Biol Phys. 2007;69:1335, author reply 1335.
22. Kyritsis AP, Giannopoulos S. Diagnosis and Management of Multifocal Gliomas. Oncology 2010;79:306–12.
23. Pouratian N, Crowley RW, Sherman JH, et al. Gamma Knife radiosurgery after radiation therapy as an adjunctive treatment for glioblastoma. J Neurooncol. 2009;94:409–18.
24. Elliott RE, Parker EC, Rush SC, et al. Efficacy of gamma knife radiosurgery for small-volume recurrent malignant gliomas after initial radical resection. World Neurosurg. 2011;76:128–40 [discussion: 161–2].
25. Cohen MH, Shen YL, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist. 2009;14:1131–8.